PCOS and Letrozole: How the Fertility Treatment Works

The short answer

Letrozole is the first-line medicine for inducing ovulation in polycystic ovary syndrome (PCOS), now renamed polyendocrine metabolic ovarian syndrome (PMOS). It is a nonsteroidal aromatase inhibitor, approved to treat breast cancer, that is used off-label to lower estrogen briefly, which prompts the body to stimulate the ovary and release an egg. [4] Guidelines recommend it over clomiphene, and in the largest trial it produced more live births, 27.5% versus 19.1%, with higher ovulation rates. [1] [2] A 42-trial meta-analysis confirmed the advantage. [3] It is taken early in the cycle before conception, not during pregnancy, and needs a clinician's monitoring. [4]

What you’ll learn

Letrozole is the guideline-recommended first-line medicine for ovulation induction in the condition, chosen over clomiphene. [2]
In the largest head-to-head trial, letrozole led to a live birth in 27.5 percent of women versus 19.1 percent on clomiphene, and to higher ovulation rates (61.7 versus 48.3 percent). [1]
A meta-analysis of 42 trials and 7,935 women confirmed higher live-birth and pregnancy rates, with similar rates of ovarian hyperstimulation. [3]
Letrozole is an aromatase inhibitor approved for breast cancer; its use for ovulation induction is off-label but strongly evidence-supported. [4]
It is taken for a few days early in the cycle, before conception, and requires monitoring, so it is a clinician-directed treatment, not a self-start option. [4]

If a clinician has suggested letrozole for polycystic ovary syndrome (PCOS), you may be surprised to learn it is technically a breast cancer drug. That is not a mistake. Letrozole has become the first-line medicine for inducing ovulation in PCOS, and the evidence behind that choice is some of the clearest in fertility care.

PCOS, renamed polyendocrine metabolic ovarian syndrome (PMOS) in 2026, causes infertility largely by disrupting ovulation. Letrozole works directly on that problem, and it does so more effectively than the older standard, clomiphene.

How letrozole works

Letrozole is a nonsteroidal aromatase inhibitor. Its approved use is to treat breast cancer in women who have gone through menopause, by lowering estrogen. [4] In fertility care, that same estrogen-lowering effect is used deliberately and briefly: taking letrozole for a few days early in the cycle drops estrogen, which prompts the brain to release more of the hormones that mature and release an egg. In many women with the condition who were not ovulating, that restarts ovulation.

Using it this way is off-label, meaning it is not the use printed on the label, but it is strongly evidence-supported and guideline-recommended. [2] [4] Because it is taken only in the early, pre-ovulation window, it is out of the body before a pregnancy would begin, which matters because it can harm a fetus if taken during pregnancy. [4]

What the trials show

The evidence for letrozole is unusually strong for a fertility treatment.

Article table: Measure, Letrozole, Clomiphene
Measure	Letrozole	Clomiphene
Cumulative live birth (largest trial)	27.5%	19.1% [1]
Ovulation rate per cycle (largest trial)	61.7%	48.3% [1]
Meta-analytic live-birth advantage	Higher (42 trials, 7,935 women)	Reference [3]
Guideline position	First-line, recommended over clomiphene [2]	Alternative

In the largest head-to-head trial, which randomized 750 women, letrozole led to more cumulative live births than clomiphene (27.5 versus 19.1 percent) and a higher ovulation rate (61.7 versus 48.3 percent). [1] A Cochrane meta-analysis of 42 trials and 7,935 women confirmed that letrozole improves live-birth and pregnancy rates compared with clomiphene, while ovarian hyperstimulation rates were similar between the two. [3] On that basis, the 2023 international guideline recommends letrozole as first-line and specifically advises using it rather than clomiphene. [2]

For how letrozole fits among the other choices, see polycystic ovary syndrome treatments ranked by the evidence, and for the metabolic medicines often used alongside it, see metformin for polycystic ovary syndrome after menopause and inositol for polycystic ovary syndrome.

Cautions and monitoring

Letrozole is well studied, but it is still a prescription medicine that needs oversight. It is taken for a few days early in the cycle, and clinicians monitor the response to time intercourse or further treatment and to limit the chance of a multiple pregnancy. [4] Common effects can include fatigue, hot flashes, and headaches, reflecting the temporary drop in estrogen. Because it can harm a fetus, it is not taken once pregnancy is possible in that cycle. [4] None of this is a reason to avoid it; it is the reason it is prescribed and monitored rather than bought over the counter.

Where the evidence is limited, and the midlife angle

It is honest to note the limits. The strongest trials studied ovulation and live birth in women actively trying to conceive with the condition as the main issue; results vary with age, weight, insulin resistance, and other fertility factors. [1] Fertility also declines with age, so a woman in her early 40s faces different odds than one in her late 20s, even on the same medicine.

There is a fitting symmetry worth naming: the same drug that induces ovulation in younger women with the condition is approved to treat breast cancer after menopause. [4] It is a reminder that the syndrome itself is lifelong. After the fertility years, its insulin resistance and cardiovascular risks persist and rise, so screening for blood sugar with tests like A1c (hemoglobin A1c) or a glucose tolerance test, and for cardiovascular risk, continues to matter into your 40s and 50s. See polycystic ovary syndrome after menopause and insulin resistance.

Who this fits

Letrozole fits women with the condition who are not ovulating regularly, are trying to conceive, and have no other major infertility factors, which is exactly the group the guideline addresses. [2] It is a strong first choice for that group.

It is a poor fit for anyone who is or might be pregnant, and it is not a self-start medicine; it needs prescribing and monitoring. If other infertility factors are present, or if letrozole cycles do not work, a fertility specialist can layer in other options.

Red flags worth attention

Any chance you are already pregnant, which is a reason to stop and confirm before taking letrozole.
Severe pelvic pain, rapid bloating, or shortness of breath during a treatment cycle, which are warning signs of ovarian hyperstimulation and need prompt care.
Cycles that repeatedly fail to produce ovulation, which should prompt a review of the plan.

What to ask your clinician

Am I a good candidate for letrozole, or are there other infertility factors to address first?
What dose and cycle-day schedule will I use, and how will we monitor ovulation?
How many cycles should we try before reassessing?
What side effects should I expect, and which warrant a call?
How do we make sure I am not taking it once pregnancy is possible?
What are the next steps if letrozole does not work for me?

Bottom line

Letrozole is the first-line medicine for inducing ovulation in the condition, and the evidence supports that status: it produced more live births than clomiphene in the largest trial and across a 42-trial meta-analysis, which is why guidelines recommend it over clomiphene. [1] [2] [3]

It works by briefly lowering estrogen to trigger ovulation, is taken early in the cycle before conception, and needs a clinician's monitoring because it is used off-label and must not be present during pregnancy. [4] Used that way, it is one of the most effective and best-supported tools for infertility related to the condition.

References

[1] Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119-29. doi:10.1056/nejmoa1313517 https://pubmed.ncbi.nlm.nih.gov/25006718/

[2] Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189(2):G43-G64. https://pmc.ncbi.nlm.nih.gov/articles/PMC10505534/

[3] Franik S, Eltrop SM, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2018;5(5):CD010287. doi:10.1002/14651858.cd010287.pub3 https://pubmed.ncbi.nlm.nih.gov/29797697/

[4] MedlinePlus. Letrozole. U.S. National Library of Medicine. https://medlineplus.gov/druginfo/meds/a698004.html

Common questions

How does letrozole help with PCOS fertility?

It briefly lowers estrogen. As an aromatase inhibitor, letrozole reduces estrogen production for a few days, which prompts the brain to increase the hormones that mature and release an egg. That restarts ovulation in many women with the condition who were not ovulating. [4][4]

Is letrozole better than clomiphene for PCOS?

The evidence says yes. In the largest trial, letrozole produced more live births than clomiphene (27.5 versus 19.1 percent) and higher ovulation rates, and a 42-trial meta-analysis agreed. Guidelines recommend letrozole over clomiphene for these reasons. [1] [2] [3][1][2][3]

What is the success rate of letrozole for PCOS?

In the largest trial, 27.5 percent of women with the condition taking letrozole had a live birth over the study, with an ovulation rate of about 61.7 percent per cycle. Individual odds vary with age, weight, and other factors, so this is an average, not a personal certainty. [1][1]

Is letrozole safe, and are there cautions?

It is taken only in the early, pre-ovulation days of the cycle, before a possible pregnancy, because it can harm a fetus if taken during pregnancy. It needs clinician monitoring to time ovulation and limit multiple pregnancy, and it is used off-label for fertility. [4][4]